We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Withholds NDA for MS Drug Laquinimod Following FDA Talks
The item has been added to your shopping cart.
Teva Withholds NDA for MS Drug Laquinimod Following FDA Talks
February 20, 2012
After recent discussions with the FDA, Teva Pharmaceuticals has decided not to file an NDA for relapsing remitting multiple sclerosis (RRMS) treatment laquinimod but plans to keep developing and studying the drug.